蛋白酶体抑制剂在多发性骨髓瘤治疗中的临床应用。
Clinical use of proteasome inhibitors in the treatment of multiple myeloma.
作者信息
Merin Noah M, Kelly Kevin R
机构信息
Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA.
出版信息
Pharmaceuticals (Basel). 2014 Dec 24;8(1):1-20. doi: 10.3390/ph8010001.
Abstract
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
摘要
多发性骨髓瘤（MM）是一种无法治愈的血液系统恶性肿瘤，其特征为肿瘤性浆细胞的克隆性增殖。蛋白酶体抑制剂用于MM治疗已使治疗结果有了显著改善。本文综述了两种已获批的蛋白酶体抑制剂（硼替佐米和卡非佐米）的使用数据，以及正在研发的新型药物。重点介绍了蛋白酶体抑制剂的临床应用，包括副作用的管理以及与其他药物的联合使用。
相似文献
1
Clinical use of proteasome inhibitors in the treatment of multiple myeloma.蛋白酶体抑制剂在多发性骨髓瘤治疗中的临床应用。
Pharmaceuticals (Basel). 2014 Dec 24;8(1):1-20. doi: 10.3390/ph8010001.
2
[Proteasome inhibitors in treatment of multiple myeloma].蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用
Klin Onkol. 2013;26(1):11-8. doi: 10.14735/amko201311.
3
Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.多发性骨髓瘤中蛋白酶体抑制剂耐药的新机制。
World J Clin Oncol. 2019 Sep 24;10(9):303-306. doi: 10.5306/wjco.v10.i9.303.
4
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.广泛的免疫球蛋白产生使骨髓瘤细胞对蛋白酶体抑制敏感。
Cancer Res. 2007 Feb 15;67(4):1783-92. doi: 10.1158/0008-5472.CAN-06-2258.
5
New orally active proteasome inhibitors in multiple myeloma.新型口服蛋白酶体抑制剂在多发性骨髓瘤中的应用。
Leuk Res. 2014 Jan;38(1):1-9. doi: 10.1016/j.leukres.2013.10.018. Epub 2013 Oct 29.
6
The proteasome and proteasome inhibitors in multiple myeloma.多发性骨髓瘤中的蛋白酶体和蛋白酶体抑制剂。
Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8.
7
Safety of proteasome inhibitors for treatment of multiple myeloma.蛋白酶体抑制剂治疗多发性骨髓瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):167-183. doi: 10.1080/14740338.2017.1259310. Epub 2016 Nov 28.
8
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.临床环境中的蛋白酶体抑制剂：克服多发性骨髓瘤对蛋白酶体抑制剂耐药性的益处和策略。
Drugs R D. 2007;8(1):1-12. doi: 10.2165/00126839-200708010-00001.
9
Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.透明质酸壳和二硫键交联核胶束用于体内靶向递送硼替佐米治疗多发性骨髓瘤。
Acta Biomater. 2018 Oct 15;80:288-295. doi: 10.1016/j.actbio.2018.09.022. Epub 2018 Sep 19.
10
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.TM-233是1'-乙酰氧基胡椒酚乙酸酯的新型类似物，通过抑制JAK/STAT和蛋白酶体活性诱导骨髓瘤细胞死亡。
Cancer Sci. 2015 Apr;106(4):438-46. doi: 10.1111/cas.12616. Epub 2015 Mar 10.
引用本文的文献
1
A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.癌症治疗的新时代：靶向蛋白酶体 - Bcl - 2轴。
J Exp Clin Cancer Res. 2025 Aug 21;44(1):246. doi: 10.1186/s13046-025-03505-5.
2
Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers.天然化合物对多发性骨髓瘤的抑制作用：通过纳米颗粒载体增强。
Front Pharmacol. 2025 Jun 17;16:1589090. doi: 10.3389/fphar.2025.1589090. eCollection 2025.
3
Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.卡非佐米治疗多发性骨髓瘤：揭示心脏毒性——从机制到诊断与管理
Front Pharmacol. 2025 Mar 27;16:1570017. doi: 10.3389/fphar.2025.1570017. eCollection 2025.
4
The proteasome modulates endocytosis specifically in glomerular cells to promote kidney filtration.蛋白酶体特异性调节肾小球细胞内吞作用，促进肾脏过滤。
Nat Commun. 2024 Mar 1;15(1):1897. doi: 10.1038/s41467-024-46273-0.
5
Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome.解码秘密：构象和结构调节剂如何抑制人20S蛋白酶体。
Front Chem. 2024 Jan 8;11:1322628. doi: 10.3389/fchem.2023.1322628. eCollection 2023.
6
Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer.发现一种用于治疗非小细胞肺癌的 OTUD3 抑制剂。
Cell Death Dis. 2023 Jun 27;14(6):378. doi: 10.1038/s41419-023-05900-2.
7
Differentiated extracts from freshwater and terrestrial mollusks inhibit virulence factor production in Cryptococcus neoformans.淡水和陆生贝类的分化提取物抑制新型隐球菌毒力因子的产生。
Sci Rep. 2023 Mar 26;13(1):4928. doi: 10.1038/s41598-023-32140-3.
8
A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models.姜黄素与蛋白酶体抑制剂在多发性骨髓瘤临床前模型中的协同作用研究综述。
Integr Cancer Ther. 2023 Jan-Dec;22:15347354231159322. doi: 10.1177/15347354231159322.
9
Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.导致多发性骨髓瘤、慢性淋巴细胞白血病和非霍奇金淋巴瘤患者继发性免疫缺陷的因素：一项系统文献综述
Front Oncol. 2023 Feb 7;13:1098326. doi: 10.3389/fonc.2023.1098326. eCollection 2023.
10
Molecular targeted therapy for anticancer treatment.用于抗癌治疗的分子靶向治疗。
Exp Mol Med. 2022 Oct;54(10):1670-1694. doi: 10.1038/s12276-022-00864-3. Epub 2022 Oct 12.
本文引用的文献
1
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.复发多发性骨髓瘤患者使用单药瑞欧溶素的I期试验。
Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7.
2
Bortezomib resistance and MUC1 in myeloma.硼替佐米耐药性与骨髓瘤中的MUC1
Blood. 2014 May 8;123(19):2910-2. doi: 10.1182/blood-2014-03-563882.
3
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.蛋白酶体抑制剂——多发性骨髓瘤的分子基础及当前研究进展
J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. Epub 2014 Apr 8.
4
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.复发/难治性骨髓瘤患者接受聚乙二醇化脂质体阿霉素、硼替佐米、环磷酰胺和地塞米松的挽救治疗。
Eur J Haematol. 2014 Sep;93(3):207-13. doi: 10.1111/ejh.12325. Epub 2014 Apr 18.
5
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.靶向 MUC1-C 与硼替佐米联合作用可下调 TIGAR 并诱导 ROS 介导的骨髓瘤细胞死亡。
Blood. 2014 May 8;123(19):2997-3006. doi: 10.1182/blood-2013-11-539395. Epub 2014 Mar 14.
6
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.在多发性骨髓瘤患者中卡非佐米剂量和方案的演变：历史概述。
Cancer Treat Rev. 2014 Jul;40(6):781-90. doi: 10.1016/j.ctrv.2014.02.005. Epub 2014 Mar 1.
7
Bortezomib for the treatment of multiple myeloma.硼替佐米用于治疗多发性骨髓瘤。
Expert Rev Hematol. 2014 Apr;7(2):173-85. doi: 10.1586/17474086.2014.899144.
8
Neurotoxicity induced by antineoplastic proteasome inhibitors.抗肿瘤蛋白酶体抑制剂引起的神经毒性。
Neurotoxicology. 2014 Jul;43:28-35. doi: 10.1016/j.neuro.2014.02.001. Epub 2014 Feb 10.
9
Current strategies for treatment of relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤的当前治疗策略。
Expert Rev Hematol. 2014 Feb;7(1):97-111. doi: 10.1586/17474086.2014.882764. Epub 2014 Jan 29.
10
Proteasome inhibitor patents (2010 - present).蛋白酶体抑制剂专利（2010年至今）。
Expert Opin Ther Pat. 2014 Apr;24(4):369-82. doi: 10.1517/13543776.2014.877444. Epub 2014 Jan 23.
Zotero 插件